Pfizer seeks COVID-19 vaccine OK for 12 to 15 year olds in US | Inquirer News

Pfizer seeks COVID-19 vaccine OK for 12 to 15 year olds in US

/ 10:12 AM April 10, 2021

LOS ANGELES, CALIFORNIA - APRIL 09: Vials containing doses of the Pfizer COVID-19 vaccine are viewed at a clinic targeting minority community members at St. Patrick's Catholic Church on April 9, 2021 in Los Angeles, California. St. John's Well Child and Family Center is administering COVID-19 vaccines ?in churches across South L.A. in a broad effort to bring vaccines to minority? communities.

LOS ANGELES, CALIFORNIA – APRIL 09: Vials containing doses of the Pfizer COVID-19 vaccine are viewed at a clinic targeting minority community members at St. Patrick’s Catholic Church on April 9, 2021 in Los Angeles, California. St. John’s Well Child and Family Center is administering COVID-19 vaccines ?in churches across South L.A. in a broad effort to bring vaccines to minority? communities. Mario Tama/Getty Images/AFP (Photo by MARIO TAMA / GETTY IMAGES NORTH AMERICA / Getty Images via AFP)

WASHINGTON — Pfizer-BioNTech asked for authorization Friday to use their COVID-19 vaccine on 12 to 15-year-olds in the United States, which could mark a crucial next step toward achieving herd immunity.

The mass vaccination of teenagers would also relieve an enormous strain on parents who are juggling the demands of homeschooling their children while keeping up with jobs.

Article continues after this advertisement

The companies said in a statement that they plan to make similar requests of other regulatory authorities worldwide in coming days.

FEATURED STORIES

Their request to the US Food and Drug Administration comes after Phase 3 clinical trials of the Pfizer vaccine in 12 to 15-year-olds showed it was 100 percent effective in warding off the disease, according to the companies.

In late March they published the results of trials carried out with 2,260 adolescents in the US whom the companies said showed “robust antibody responses.”

Article continues after this advertisement

The vaccine was “well tolerated with side effects generally consistent with those observed in participants 16 to 25 years of age,” the companies said Friday.

Article continues after this advertisement

For now the vaccine has emergency authorization for use in people aged 16 and over.

Article continues after this advertisement

Children are less likely to develop severe COVID so vaccinating them has been less of a priority than getting older people inoculated.

But they do make up a large part of the community that will need to be inoculated in order to achieve herd immunity, when the proportion of people with antibodies largely prevents the spread of the virus.

Article continues after this advertisement

Experts do not know precisely what percentage of the population needs to be vaccinated to get to that point, but one of the leading US immunologists, Anthony Fauci, has put it anywhere between 70 and 85 percent.

In February, he said that US children aged 12 or under could very likely be vaccinated by the start of 2022.

The BioNTech/Pfizer shot is based on new mRNA technology and was the first COVID-19 vaccine to be approved in the West late last year.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

In March, the US biotech company Moderna said it had started trials on children aged between six months and 11 years. Johnson & Johnson, whose vaccine was the third approved for US use, has also started trials on the 12 to 17 age group.

TAGS: Pfizer, United States

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.